OBJECTIVE: To assess the impact of treatment for co-morbid sleep-disordered breathing (SDB) on patients with nightmares and post-traumatic stress. METHODS: Twenty-three chronic nightmare sufferers (15 with post-traumatic stress disorder, PTSD) who also suffered co-morbid SDB (obstructive sleep apnea, OSA, n=16; upper airway resistance syndrome, UARS, n=7) completed a telephone interview, on average, 21 months after having been offered treatment for SDB at a university sleep disorders clinic. RESULTS: At follow-up, 14 reported maintaining treatment (Treatment Group) and 9 reported discontinuing treatment (No-Treatment Group). More patients in the Treatment Group reported improvement in sleep (93% vs. 33%) and in daytime well being (93% vs. 33%) compared with those in the No-Treatment group. The Treatment Group reported a median improvement in nightmares of 85% compared with a median 10% worsening in the No-Treatment Group. In the PTSD subset (n=15), nine in the Treatment Group reported a median 75% improvement in PTSD symptoms whereas six in the No-Treatment Group reported a median 43% worsening. CONCLUSION: In this small sample of patients, treatment of SDB was associated with improvements in nightmares and PTSD. Relationships between nightmares, PTSD and SDB are discussed.
OBJECTIVE: To assess the impact of treatment for co-morbid sleep-disordered breathing (SDB) on patients with nightmares and post-traumatic stress. METHODS: Twenty-three chronic nightmare sufferers (15 with post-traumatic stress disorder, PTSD) who also suffered co-morbid SDB (obstructive sleep apnea, OSA, n=16; upper airway resistance syndrome, UARS, n=7) completed a telephone interview, on average, 21 months after having been offered treatment for SDB at a university sleep disorders clinic. RESULTS: At follow-up, 14 reported maintaining treatment (Treatment Group) and 9 reported discontinuing treatment (No-Treatment Group). More patients in the Treatment Group reported improvement in sleep (93% vs. 33%) and in daytime well being (93% vs. 33%) compared with those in the No-Treatment group. The Treatment Group reported a median improvement in nightmares of 85% compared with a median 10% worsening in the No-Treatment Group. In the PTSD subset (n=15), nine in the Treatment Group reported a median 75% improvement in PTSD symptoms whereas six in the No-Treatment Group reported a median 43% worsening. CONCLUSION: In this small sample of patients, treatment of SDB was associated with improvements in nightmares and PTSD. Relationships between nightmares, PTSD and SDB are discussed.
Authors: Peter J Colvonen; Tonya Masino; Sean P A Drummond; Ursula S Myers; Abigail C Angkaw; Sonya B Norman Journal: J Clin Sleep Med Date: 2015-04-15 Impact factor: 4.062
Authors: Vincent Mysliwiec; Panagiotis Matsangas; Jessica Gill; Tristin Baxter; Brian O'Reilly; Jacob F Collen; Bernard J Roth Journal: J Clin Sleep Med Date: 2015-12-15 Impact factor: 4.062
Authors: Scott G Williams; Jacob Collen; Nicholas Orr; Aaron B Holley; Christopher J Lettieri Journal: Sleep Breath Date: 2014-04-22 Impact factor: 2.816
Authors: Jeremy E Orr; Carolina Smales; Thomas H Alexander; Carl Stepnowsky; Giora Pillar; Atul Malhotra; Kathleen F Sarmiento Journal: J Clin Sleep Med Date: 2017-01-15 Impact factor: 4.062